Abstract

Pannexin 1 (Panx1) is a membrane channel implicated in numerous physiological and pathophysiological processes via its ability to support release of ATP and other cellular metabolites for local intercellular signaling. However, to date, there has been no direct demonstration of large molecule permeation via the Panx1 channel itself, and thus the permselectivity of Panx1 for different molecules remains unknown. To address this, we expressed, purified and reconstituted Panx1 into proteoliposomes and demonstrated that channel activation by caspase cleavage yields a dye-permeable pore that favors flux of anionic, large-molecule permeants (up to ~1 kDa). Large cationic molecules can also permeate the channel, albeit at a much lower rate. We further show that Panx1 channels provide a molecular pathway for flux of ATP and other anionic (glutamate) and cationic signaling metabolites (spermidine). These results verify large molecule permeation directly through activated Panx1 channels that can support their many physiological roles.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files (Source Data files). Source data files have been provided for Figure 1G, Figure 1 Supplement 1C, Figure 1 Supplement 2B-E, Figure 2D, Figure 2 Supplement 1, Figure 2 Supplement 2A-F, Figure 3B-I, Figure 4 B-D, Figure 4 Supplement 2B-C. Source code has been uploaded to Github: https://github.com/VolkerKirchheim/VK_TIRFsinglevesicleStep1. Data is also available on Dryad under doi:10.5061/dryad.s1rn8pk69

The following data sets were generated

Article and author information

Author details

  1. Adishesh K Narahari

    Pharmacology, University of Virginia, Charlottesville, United States
    For correspondence
    akn4uq@virginia.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8708-9161
  2. Alex J B Kreutzberger

    Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9774-115X
  3. Pablo S Gaete

    Department of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3373-9138
  4. Yu-Hsin Chiu

    Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4730-8104
  5. Susan A Leonhardt

    Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Christopher B Medina

    Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Xueyao Jin

    Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Patrycja W Oleniacz

    Pharmacology, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Volker Kiessling

    Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9388-5703
  10. Paula Q Barrett

    Pharmacology, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Kodi S Ravichandran

    Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Mark Yeager

    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Jorge E Contreras

    Department of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9203-1602
  14. Lukas K Tamm

    Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1674-4464
  15. Douglas Bayliss

    Pharmacology, University of Virginia, Charlottesville, United States
    For correspondence
    bayliss@virginia.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5630-2572

Funding

National Institutes of Health (P01 HL120840)

  • Kodi S Ravichandran
  • Mark Yeager
  • Douglas Bayliss

Ministry of Science and Technology, Taiwan (108-2320-B-007-007-MY2)

  • Yu-Hsin Chiu

National Institutes of Health (T32 GM007267)

  • Adishesh K Narahari

University of Virginia (Whitfield-Randolph Scholarship)

  • Adishesh K Narahari

National Institutes of Health (R01 HL138241)

  • Paula Q Barrett

National Institutes of Health (R01 GM099490)

  • Jorge E Contreras

National Institutes of Health (R01 HL48908)

  • Mark Yeager

National Institutes of Health (R01 GM138532)

  • Mark Yeager

National Institutes of Health (P01 GM072694)

  • Lukas K Tamm

National Institutes of Health (R01 GM051329)

  • Lukas K Tamm

National Institutes of Health (F30 CA236370)

  • Adishesh K Narahari

National Institutes of Health (T32 GM007055)

  • Adishesh K Narahari
  • Christopher B Medina

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Baron Chanda, Washington University in St. Louis, United States

Version history

  1. Received: November 11, 2020
  2. Accepted: January 5, 2021
  3. Accepted Manuscript published: January 7, 2021 (version 1)
  4. Version of Record published: January 13, 2021 (version 2)

Copyright

© 2021, Narahari et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,173
    views
  • 495
    downloads
  • 55
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Adishesh K Narahari
  2. Alex J B Kreutzberger
  3. Pablo S Gaete
  4. Yu-Hsin Chiu
  5. Susan A Leonhardt
  6. Christopher B Medina
  7. Xueyao Jin
  8. Patrycja W Oleniacz
  9. Volker Kiessling
  10. Paula Q Barrett
  11. Kodi S Ravichandran
  12. Mark Yeager
  13. Jorge E Contreras
  14. Lukas K Tamm
  15. Douglas Bayliss
(2021)
ATP and large signaling metabolites flux through caspase-activated Pannexin 1 channels
eLife 10:e64787.
https://doi.org/10.7554/eLife.64787

Share this article

https://doi.org/10.7554/eLife.64787

Further reading

    1. Structural Biology and Molecular Biophysics
    Hitendra Negi, Aravind Ravichandran ... Ranabir Das
    Research Article

    The proteasome controls levels of most cellular proteins, and its activity is regulated under stress, quiescence, and inflammation. However, factors determining the proteasomal degradation rate remain poorly understood. Proteasome substrates are conjugated with small proteins (tags) like ubiquitin and Fat10 to target them to the proteasome. It is unclear if the structural plasticity of proteasome-targeting tags can influence substrate degradation. Fat10 is upregulated during inflammation, and its substrates undergo rapid proteasomal degradation. We report that the degradation rate of Fat10 substrates critically depends on the structural plasticity of Fat10. While the ubiquitin tag is recycled at the proteasome, Fat10 is degraded with the substrate. Our results suggest significantly lower thermodynamic stability and faster mechanical unfolding in Fat10 compared to ubiquitin. Long-range salt bridges are absent in the Fat10 structure, creating a plastic protein with partially unstructured regions suitable for proteasome engagement. Fat10 plasticity destabilizes substrates significantly and creates partially unstructured regions in the substrate to enhance degradation. NMR-relaxation-derived order parameters and temperature dependence of chemical shifts identify the Fat10-induced partially unstructured regions in the substrate, which correlated excellently to Fat10-substrate contacts, suggesting that the tag-substrate collision destabilizes the substrate. These results highlight a strong dependence of proteasomal degradation on the structural plasticity and thermodynamic properties of the proteasome-targeting tags.

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics
    Samuel C Griffiths, Jia Tan ... Hsin-Yi Henry Ho
    Research Article Updated

    The receptor tyrosine kinase ROR2 mediates noncanonical WNT5A signaling to orchestrate tissue morphogenetic processes, and dysfunction of the pathway causes Robinow syndrome, brachydactyly B, and metastatic diseases. The domain(s) and mechanisms required for ROR2 function, however, remain unclear. We solved the crystal structure of the extracellular cysteine-rich (CRD) and Kringle (Kr) domains of ROR2 and found that, unlike other CRDs, the ROR2 CRD lacks the signature hydrophobic pocket that binds lipids/lipid-modified proteins, such as WNTs, suggesting a novel mechanism of ligand reception. Functionally, we showed that the ROR2 CRD, but not other domains, is required and minimally sufficient to promote WNT5A signaling, and Robinow mutations in the CRD and the adjacent Kr impair ROR2 secretion and function. Moreover, using function-activating and -perturbing antibodies against the Frizzled (FZ) family of WNT receptors, we demonstrate the involvement of FZ in WNT5A-ROR signaling. Thus, ROR2 acts via its CRD to potentiate the function of a receptor super-complex that includes FZ to transduce WNT5A signals.